Cancer Drug Firm Duped Investors In $26M Offering: Suit
Satish Shah launched the suit on behalf of investors in Gaithersburg, Md.-based GenVec, alleging the company artificially inflated its stock price through a series of misleading press releases before announcing in March 2010 that the treatment, TNFerade, had foundered during a pivotal clinical study called a PACT trial.
“Defendants knew or recklessly disregarded...
Already a subscriber? Click here to login